arrow
F

Florence Joly

hospital universitari vall d'hebron
H指数:73
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma)

一项Ib/II期、开放标签、多中心、随机伞式研究,评估阿替利珠单抗与萨喜妥珠单抗戈维他胺联用对既往接受过铂类治疗方案治疗的局部晚期或转移性尿路上皮癌患者的疗效(MORPHEUS-Urothelial Carcinoma)

2026-07-010
OAAI
Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial

新辅助免疫检查点阻断在宫颈鳞癌患者化疗放疗前的应用(GINECO window-of-opportunity COLIBRI研究):一项II期临床试验

2026-01-050
OAAI
Impact of androgen receptor pathway inhibitors on cognitive function in older adults treated for metastatic prostate cancer

雄激素受体通路抑制剂对接受转移性前列腺癌治疗老年患者认知功能的影响

2025-12-230
OAAI
Virtual reality-based cognitive rehabilitation programme to support employment in patients with breast cancer: protocol for the Cog-RV pilot study

基于虚拟现实技术的认知康复计划以支持乳腺癌患者的就业:Cog-RV探索性研究的方案

2025-12-150
OA
Surgical Approach and Maintenance Therapy in Advanced Low-Grade Serous Ovarian Cancer: Insights from the French ESME Database

晚期低级别浆液性卵巢癌的手术治疗与维持治疗:来自法国ESME数据库的见解

2025-11-140
PRE
Remotely supervised online cognitive training to reduce cognitive difficulties following chemotherapy in patients treated for localized breast cancer: Protocol of the Cog-Stim2 multicenter randomized controlled trial

远程监督的在线认知训练以减少局部乳腺癌治疗后化疗患者的认知困难:Cog-Stim2多中心随机对照试验方案

2025-11-130
PRE
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study

转移性透明细胞肾细胞癌中的Nivolumab: 来自NIVOREN getug-afu 26 2期研究的综合生物标志物分析

2025-11-110
PRE
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial

奥拉帕利维持治疗在铂类为基础化疗后的晚期/转移性子宫内膜癌中的应用:GINECO随机IIb期UTOLA试验

2025-08-260
OAAI
DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients

DOMENICA:dostarlimab与单药化疗相比,用于一线治疗MMR缺乏的晚期子宫内膜癌患者

2025-05-050
PRE
Causal analyses of the impact of comorbid conditions and concomitant medications on response to neoadjuvant chemotherapy in breast cancer: analysis of a multicenter prospective cohort study (CANTO)

乳腺癌新辅助化疗中合并症和联合用药对疗效影响的因果分析:一项多中心前瞻性队列研究(CANTO)分析

2025-05-010
OA
Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer (CHIPOR): A Randomized, Open-Label, Phase 3 Trial Editorial comment

腹腔热灌注化疗治疗复发性卵巢癌(CHIPOR):一项随机、开放标签、III期试验编辑评论

2025-05-010
PRE
Neurocognitive impact of different irradiation modalities for patients with grade I-II skull base meningioma: a prospective multi-arm cohort study (CANCER COG) (vol 20, 16, 2025)

不同放射治疗模式对I-II级颅底脑膜瘤患者的神经认知影响:一项前瞻性多臂队列研究(CANCER COG)(第20卷,第16期,2025年)

2025-04-290
OA
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial

非透明细胞肾细胞癌中,伊匹木单抗/纳武利尤单抗对比标准护理的 prospective randomized phase-II trial - SUNNIFORECAST trial 的结果

2025-04-010
OA
Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA-1/ENGOT-ov25
2024-12-011
PRE
A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance 2 years later

乳腺癌诊断中系统性炎症的生物行为模型和2年后临床重要性的乏力

2024-11-011
OAAI